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Coronavirus Disease 2019 (COVID-19), a viral respiratory pandemic, has rapidly spread throughout the globe.
Large scale and rapid testing of the population is required to contain the disease, but such testing is prohibitive in
terms of resources, cost and time. Recently RT-PCR based pooled testing has emerged as a promising way to
boost testing efficiency. We introduce a stepped pooled testing strategy, a probability driven approach which
significantly reduces the number of tests required to identify infected individuals in a large population. Our
comprehensive methodology incorporates the effect of false negative and positive rates to accurately determine
not only the efficiency of pooling but also it’s accuracy. Under various plausible scenarios, we show that this
approach significantly reduces the cost of testing and also reduces the effective false positive rate of tests when
compared to a strategy of testing every individual of a population. We also outline an optimization strategy to
obtain the pool size that maximizes the efficiency of pooling given the diagnostic protocol parameters and local
infection conditions.
I. INTRODUCTION
Coronavirus Disease 2019 (COVID-19), a viral infectious respiratory illness, has recently emerged as a major threat to public health
and economic stability in countries around the world. It has spread globally at an alarming pace and World Health Organization
(WHO) has declared it a pandemic. In absence of a cure or a vaccine, large scale testing and quarantine is recognized as one of the
most effective strategies for containing its spread. While there are various known diagnostic methods for COVID-19 including
nucleic acid testing, protein testing and computed tomography [1], they can be extremely prohibitive in terms of cost and time.
Pooled testing is a promising strategy to boost testing efficiency. In pooled testing, several samples from each patient are divided
and grouped into various pools and the pool is then tested for the disease. If the pool tests negative, each sample of the pool must
be negative too. This basic idea reduces the overall cost and time of testing large populations.
Pooled testing was first proposed during World War II [2] and has been a part of diagnostic methodology ever since [3]. It has
since been employed several times to test for infections ranging including Malaria [4], Flu [5] and HIV [6, 7]. One of the first
implementations of laboratory pooled testing for COVID-19 was demonstrated by Yelin et al [8] for pools as large as 32 or 64
samples. Today, Physicians and Public Health Officials from India [9–15] and many other countries around the globe [16–20] are
using pooled testing for determine the spread of this pandemic in a rapid and cost efficient manner.
A variety of different strategies have been proposed over the past several years to implement pooled testing [21, 22]. They
can be broadly classified into two types: adaptive and non-adaptive. Adaptive methods [22–30] employ a sequential testing
approach, thus requiring fewer number of total tests but more time as each step of testing informs the next. On the other hand,
non-adaptive pooled testing methods [29, 31, 32] usually involve a matrix type pooling that allows for simultaneous testing of
several pools whose results are then collated to pinpoint to infected samples. These methods are faster but can require a greater
number of tests in total. While many of these methods might be mathematically efficient, their practical implementation is usually
challenging [8, 29] and limits the complexity that can be incorporated, no matter the benefits. Hence, it is imperative to modify
and verify any proposed method according to clinical constraints.
Here, we present a probability driven pooled testing approach that can significantly reduce the number of tests required to identify
infected patients in large populations. The method divides and tests pools of samples in a hierarchical (stepped) manner. This
approach is general enough to not be limited to COVID-19 alone and can be applied to other infectious scenarios with minor
modifications. The mathematical model used for implementing and optimizing this strategy is presented along with representative
results for various probable real-life scenarios. Under various plausible scenarios, this strategy reduces the cost of testing between
30% to 90% compared to a strategy of individually testing everyone in a population and cuts the false positive rate up to one-third
of an individual test.
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2Parameter Name Description
M Pool (group) size
β Fraction of the Population infected
Inputs f+ False positives rate for a test
f− False negatives rate for a test
Nmax Maximum number of tests possible per patient
Outputs K Efficiency Amplification Factor compared to testing individually. (This is also the average effective
number of people that can be tested per test)
Fpool− False Negative rate for the complete stepped pooled testing (Different from f−)
TABLE I. List of parameters used for Analysis and Results
It can be used to rapidly determine the efficiency boost that can be obtained by pooling a desired number of samples together if we
know the accuracy of testing method and the rate of infection in the population being tested. It can also suggest optimal pool size
that should be used to minimize the number of tests needed per 1000 people.
II. METHODOLOGY
The stepped pooled testing strategy is applicable to any testing method that involves sample collection such as the Reverse
Transcription – Polymerase Chain Reaction (RT-PCR) [1] test which is being widely used for testing COVID-19. We begin by
assuming that the sample(s) collected from the patients are enough for Nmax tests only (for instance if we are able to collect 3
swabs per patient then Nmax = 3). This number will determines the number of steps of the stepped pooled testing strategy.
Our strategy extends the 2-step model described in Hanel and Thurner [30]. The stepped pooled testing strategy goes as follows:
1. We test a pool of M samples.
2. If the outcome is negative (not infected) we can surmise that all the M samples in the pool are infection free.
3. If the pooled sample is tested positive (infected), we split the samples from these M patients into two sub pools of size M/2
each and repeat steps 1 and 2. It should be noted that at every step of this process we need to use a fresh sample from the
patient to make new sub-pools because the sample from the previous step is not reusable.
4. This process is repeated Nmax − 1 times, after which we are left with a single sample of the patients in the sub-pools. If a
sub-pool at this stage yields positive for infection, we individually test every patient in this sub-pool.
It can be observed that this strategy is most effective when the the pool size M is an integer multiple of M/2Nmax−2. The initial size
of the pool M can be optimized to maximize the effective number of people tested per test or equivalently, minimize the number of
tests needed per 1000 people. A flowchart for this strategy is shown in Fig. 1.
Probabilistic calculations along this tree enable us to estimate the expected number of tests to be done for a pool of given size as
well as the overall chances of false negatives. The probability of a pool of M samples being infected (i.e. at least 1 out of M
positive) is
p(M) = 1 − (1 − β)M . (1)
The probability of the pooled testing positive is [33]
G+(M) = p(M)(1 − f−) + (1 − p(M)) f+ = p(M)(1 − f− − f+) + f+ . (2)
Note that we have assumed that the false negative and positive rate for pool of samples is the same as that for a single sample. This
can be justified based on the limits of detection for the commonly used RT-PCR protocols. Please refer to Appendix A for details.
Following the flowchart in Fig. 1, we can deduce that T(M), the expected number of tests for a pool of size M, is given by a
recursive function Zˆ(M, s) that terminates when we get to Nmax steps:
T(M) = Zˆ(M, Nmax) (3)
Zˆ(m, s) =
{
1 + 2G+ Zˆ(m/2, s − 1) for s > 1
m for s = 1
(4)
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FIG. 1. Flowchart (Decision Tree) representing the testing method for a pool of M samples. If a pool sample is tested negative (−), the procedure
is stopped for that pool sample.
Here m denotes the subpool size and s denotes the step number.
It follows that the number of persons per test, which we call the test efficiency amplification K , is given by
K =
M
T
. (5)
Correspondingly, the number of tests needed per 1000 people is
T1000 =
1000
K
=
1000T
M
. (6)
The total probability of showing a false positive at the end of all steps can also be calculated using a recursive formula. To better
understand the calculation for this step, it helps to write the probabilities at each step as shown in Fig. 5. The recursive formula for
the pooled test false negative Fpool− can then be written as
Fpool− = Uˆ(M, Nmax) (7)
Uˆ(m, s) =
{
p(m) f− + 2p(m)(1 − f−)Uˆ(m/2, s − 1) for s > 1
f−/2 for s = 1 . (8)
Here m denotes the subpool size and s denotes the step number.
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FIG. 2. Effect of population infection rate β. Tests required per 1000 people (left) and pool test false negative percentage (right) as a function
of pool size. We assume number of steps Nmax = 2, a false positive rate of f+ = 0.12% and a false negative rate of f− = 15%.
III. RESULTS
Indian Council of Medical Research (ICMR) recently published guidelines [34] for pool testing and suggested limiting the pool
size M to 5 to avoid dilution. ICMR also suggested a staggered approach to use of pooled testing: (a) for areas with infection rate
in the population less than 2% pooled testing should be used, (b) For infection rate between 2 − 5%, pooled testing should be used
for community and asymptomatic patient testing, and (c) for areas with infection rate > 5%, pooled testing should not be used. We
will use these numbers as a guide for demonstrating our method. It should be noted that higher pool sizes, up-to M = 64, have been
reported in other studies [8]. These are also in agreement with our calculations regarding limits of detection (See Appendix A).
In Figs. 2 to 4, we show the results for a representative set of parameters. We find that the number of tests per 1000 people
decreases and the false negatives increases as we make the pool size larger. However, there is an optimum pool size that achieves
maximum efficiency (i.e. minimum T1000).
Figure 2 reveals that for the same pool size, a higher infection rate population requires more tests and will have an overall lower
accuracy (higher false negative rate). This is consistent with what we would expect clinically. In Fig. 3, we obtain the effect of false
negative rate on stepped pooled testing. Interestingly, a diagnostic test with higher false negative would go through more samples
in a fewer number of tests but at the cost of overall higher pool test false negative making this trade-off possibly undesirable.
In Fig. 4, we see the effect of the number of steps, Nmax (also the number of samples per patient) on the pooling strategy. Similar
to the previous two parameter sweeps, we notice that the test required per 1000 people shows a non-monotonic behavior and
has an optimal pool size for which the pooling is most efficient (Note that for Nmax = 4, T1000 minimizes at M = 48 which is
beyond the visible horizontal axis). On the other hand, the false negative rate steadily increases but still remains below the false
negative rate of a single test. It is obvious that using multiple samples significantly reduces the number of tests needed without
compromising the overall false negative of the pooling strategy.
Table II summarizes the results for a broad set of plausible scenarios to demonstrate the efficiency of this strategy. In addition to
predicting the efficiency and accuracy of different pooling strategies, we can also this method to calculate the optimal pool size
that leads to the least number of tests (i.e. minimizes T1000). Figures 2 to 4 clearly demonstrate the existence of such an optimum.
In Table III, we show various possible testing scenarios and the corresponding optimal pool size. The results in this section show
that stepped pooled testing can reduce the overall pool false negative rate below the false negative rate of an individual test.
IV. CONCLUSION
We propose a new stepped pooled testing strategy that can significantly reduce the cost of testing a large population. The strategy
also reduces the chances of false negative in almost all scenarios because an infected patient’s sample is likely to be tested multiple
times. Even in the simplest case with two samples per individual (i.e. two steps, also called Dorfman Pooling [2]) and an initial
pool size of 2, we can significantly reduce the number of tests required per 1000 individuals, by up to 33.7% for populations with
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FIG. 3. Effect of false negative rate f−. Tests required per 1000 people (left) and pool test false negative percentage (right) as a function of
pool size. We assume number of steps Nmax = 2, an infection rate β = 2% and a false negative rate f− = 15%.
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FIG. 4. Effect of number of steps Nmax. Tests required per 1000 people (left) and pool test false negative percentage (right) as a function
of pool size for Nmax = 2 and Nmax = 4. We assume an infection rate of β = 2%, a false negative rate f− = 15% and a false positive rate
f+ = 0.12%.
a high infection rate and up to 46.5% for populations with a low infection rate. As the number of steps and initial pool size is
increased, the testing efficiency progressively improves, albeit at the cost of slightly higher false negative rate. Never the less,
barring the cases with very high infection rate, the pooled false negative rate is still below that of an individual test.
Based on our results, we make several suggestions about the effective pool size and the number of samples that should be collected
from an individual. This methodology should be customized dynamically and regularly based on evolving local levels of infection.
Most significant benefits of this strategy can be realized by collecting 2 or 3 samples from each individual and pooling them into
groups of 4 to 6. Increasing the number of steps Nmax means collecting more samples from each patient being tested. Hence, the
value of Nmax should be chosen pragmatically based on consultation with the physician or health professional. Finally, we note
that machine learning methods may be implemented to utilize data collected on disease spread and dynamically adapt this strategy
for maximum efficiency. We leave this as a topic for future research.
6Infection Rate (β) Number of Steps Nmax Pool Size (M)
Test Needed Per
1000 People T1000
Pool Test False
Negative Fpool− %
Testing Cost
Reduction (%)
2 2 535 1.10 46.5
2 3 385 1.63 61.5
2% (Low) 2 5 283 2.67 71.7
3 4 286 1.31 71.4
3 6 205 2.03 79.5
4 8 162 2.57 83.8
2 2 584 2.70 41.6
2 3 456 3.96 54.4
5% (Medium) 2 5 394 6.27 60.6
3 4 343 3.64 65.7
3 6 267 5.76 73.3
4 8 224 7.13 77.6
2 2 663 5.27 33.7
2 3 565 7.52 43.5
10% (High) 2 5 549 11.36 45.1
3 4 445 8.24 55.5
3 6 392 13.02 60.8
4 8 341 16.52 65.9
TABLE II. Testing cost reduction from stepped pool strategy. We show the overall testing cost reduction for various plausible scenarios
outlined by ICMR. We assume a false negative rate f− = 15% and a false positive rate f+ = 0.12%.
Optimal Pool
Size (M)
Test Needed Per
1000 People T1000
Pool Test False
Negative Fpool− %
Testing Cost
Reduction (%)
2% 8 253 4.14 74.7
Infection Rate (β) 5% 6 393 7.35 60.7
10% 4 544 9.54 45.6
5% 8 268 1.46 73.2
False negative 15% 8 253 4.14 74.7
rate ( f−) 30% 9 229 8.48 77.1
40% 10 211 11.71 78.9
2 8 253 4.14 74.7
Number of steps (Nmax) 3 18 122 6.96 87.8
4 32 81 12.07 91.9
TABLE III.Optimal pool size M under various scenarios. Unless specified in the first column, we use number of steps Nmax = 2, an infection
rate of β = 2%, a false negative rate f− = 15% and a false positive rate f+ = 0.12%.
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8Specimen Type
Mean (range) viral load (RNA copies/mL) in RdRp-P2-negative
but COVID-19-RdRp/Hel-positive specimens
Respiratory tract 4.33 × 104(2.85 × 103 − 4.71 × 105)
NPA/NPS/TS 1.74 × 104(2.85 × 103 − 8.40 × 104)
Saliva 5.32 × 104(1.74 × 103 − 4.71 × 105)
Sputum N/A
Non-respiratory tract 7.06 × 103(2.21 × 102 − 1.67 × 104)
Plasma 7.86 × 103(2.21 × 102 − 1.67 × 104)
Urine N/A
Feces/rectal swabs 4.38 × 103(1.54 × 103 − 6.69 × 103)
Total 3.21 × 104(2.21 × 102 − 4.71 × 105)
TABLE IV. Viral Load in respiratory and non-respiratory specimens. Reproduced from Chan et al. [37]
Appendix A: Diagnostic limit considerations for pooled testing with RT-PCR
One of the key advantages of real-time PCR assays utilizing target sequence specific primers (as is the case with all COVID-19 test
kits) is their wide dynamic range. This enables the analysis of samples with widely varying levels of target RNA. The resolving
power of RT-PCR is mostly limited by the efficiency of RNA-to-cDNA conversion, a real concern when the target RNA is scarce.
Thus, determination of the Limit of Detection (LOD)– by performing serial dilutions of the positive control sample and obtaining
standard curves– is a critical step in the validation of any testing kit/protocol. The highest dilution of the standard curve, provided
in the assay performance evaluation report of any RT-PCR assay kit, delineates the lowest concentration that can be quantified
with confidence. Thus, pooling patient samples as proposed by the current model is unlikely to influence the probability of a false
negative prediction by the assay if the effective target concentration is maintained above the LOD. However, if the intensity values
recorded are comparable to that of the LOD, they should be recorded only as a qualitative (yes/no) prediction [35].
Target RNA selection plays a big role in the assay sensitivity. These include RNA-dependent RNA polymerase (RdRp),
hemagglutinin-esterase (HE), and open reading frames ORF1a and ORF1b. World Health Organization (WHO) recommends a
first line screening with the E gene assay followed by a confirmatory assay using the RdR p gene. Tang et al. [36] developed and
compared the performance of three novel real-time RT-PCR assays targeting the RdRp/Hel, S, and N genes of SARS-CoV-2.
Among them, the COVID-19-RdRp/Hel assay had the lowest limit of detection in vitro and higher sensitivity and specificity.
In this section, we will calculate the maximum possible pool size (M∗) that is consistent with the LOD of current COVID-19 tests.
Calculation.– The LOD of the COVID-19-RdRp/Hel assay is 11.2 RNA copies/reaction [36]. Assuming a reaction volume
of 25 µL, this is equivalent 448 RNA copies in one mL sample. From Table IV, we find that the mean viral load for
nasopharyngeal/nasal swabs is 1.74× 104 RNA copies/mL. Assuming a pool size of M samples with only one infected sample, and
that samples are pooled first followed by RNA extraction, the net effective viral load in the pooled sample will be (1.74/M) × 104
copies/mL. In the standardized protocol for RNA extraction and RT-PCR procedure, 200 µL of pooled sample is diluted with 250
µL of solvent and loaded for RNA extraction. Purified RNA is diluted into 50 µL of solvent. 10 µL of diluted solution is used per
well of PCR assay with a total reaction volume of 25 µL [38].
Thus, the net effective viral load per PCR well (in units of RNA copies/mL of solvent) is
1.74 × 104
M
× 200
450
× 450
50
× 10
25
≈ 2.8 × 10
4
M
. (A1)
This quantity should be greater than the minimum LOD of the test, which is 448 RNA copies per one mL of solvent. Thus,
2.8 × 104
M
≥ 448 (A2)
or, M ≤ 62.5 (A3)
Thus, the largest possible pool size consistent with LOD of a RT-PCR test is M∗ = 62. This value is consistent with earlier
literature [8, 28].
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FIG. 5. Flowchart showing the calculation for pool test false negative. The representative values are shown on the left side of the tree.
